Literature DB >> 16095676

Age-specific ovarian cancer incidence rate patterns in the United States.

Jeffrey T Quirk, Nachimuthu Natarajan, Curtis J Mettlin.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16095676     DOI： 10.1016/j.ygyno.2005.06.052

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  20 in total

Review 1.  Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management.

Authors:  Sinead H McEvoy; Stephanie Nougaret; Nadeem R Abu-Rustum; Hebert Alberto Vargas; Elizabeth A Sadowski; Christine O Menias; Fuki Shitano; Shinya Fujii; Ramon E Sosa; Joanna G Escalon; Evis Sala; Yulia Lakhman
Journal:  Abdom Radiol (NY)       Date:  2017-10

Review 2.  Imaging of pediatric ovarian neoplasms.

Authors:  Monica Epelman; Kudakwashe R Chikwava; Nancy Chauvin; Sabah Servaes
Journal:  Pediatr Radiol       Date:  2011-05-13

Review 3.  Palliative surgery versus medical management for bowel obstruction in ovarian cancer.

Authors:  Ali Kucukmetin; Raj Naik; Khadra Galaal; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

4.  Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.

Authors:  Xiaolong Wei; David Dombkowski; Katia Meirelles; Rafael Pieretti-Vanmarcke; Paul P Szotek; Henry L Chang; Frederic I Preffer; Peter R Mueller; Jose Teixeira; David T MacLaughlin; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-15       Impact factor: 11.205

Review 5.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

6.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

Review 7.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

Review 8.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

9.  Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.

Authors:  Aasia Saleemuddin; Ann K Folkins; Leslie Garrett; Judy Garber; Michael G Muto; Christopher P Crum; Shelley Tworoger
Journal:  Gynecol Oncol       Date:  2008-08-21       Impact factor: 5.482

Review 10.  Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease.

Authors:  Albiruni Ryan Abdul Razak; Louise Li; Andrew Bryant; Ivan Diaz-Padilla
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.